Pharsight

1. Arymo Er patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549899	ZYLA	Abuse deterrent pharmaceutical compositions for controlled release	Jul, 2033 (9 years from now)
US9044402	ZYLA	Abuse-deterrent pharmaceutical compositions for controlled release	Jul, 2033 (9 years from now)

Market Authorisation Date: 09 January, 2017

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
15 mg, 30 mg and 60 mg	29 Dec, 2017	1		25 Nov, 2017	Extinguished

Strength	Dosage	Availability
30MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
15MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
60MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

ARYMO ER family patents

2. Avinza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6066339	KING PHARMS LLC	Oral morphine multiparticulate formulation	Nov, 2017 (6 years ago)

Market Authorisation Date: 20 March, 2002

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
30 mg, 60 mg, 90 mg and 120 mg	04 Jun, 2007	1	16 Jan, 2013	25 Nov, 2017	Deferred
45 mg and 75 mg	11 Aug, 2009	1		25 Nov, 2017	Extinguished

Strength	Dosage	Availability
60MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
75MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
45MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
120MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
30MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
90MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued

AVINZA family patents

3. Depodur patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5723147	PACIRA PHARMS INC	Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride	Mar, 2015 (9 years ago)
US5931809	PACIRA PHARMS INC	Epidural administration of therapeutic compounds with sustained rate of release	Jul, 2015 (8 years ago)
US5807572	PACIRA PHARMS INC	Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride	Sep, 2015 (8 years ago)
US6241999	PACIRA PHARMS INC	Method for producing liposomes with increased percent of compound encapsulated	Sep, 2016 (7 years ago)
US5997899	PACIRA PHARMS INC	Method for producing liposomes with increased percent of compound encapsulated	Sep, 2016 (7 years ago)
US6193998	PACIRA PHARMS INC	Method for producing liposomes with increased percent of compound encapsulated	Sep, 2016 (7 years ago)
US6171613	PACIRA PHARMS INC	Method for producing liposomes with increased percent of compound encapsulated	Oct, 2016 (7 years ago)
US5962016	PACIRA PHARMS INC	Multivesicular liposomes utilizing neutral lipids to modify in vivo release	Jan, 2017 (7 years ago)
US5891467	PACIRA PHARMS INC	Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes	Jan, 2017 (7 years ago)

Market Authorisation Date: 18 May, 2004

Treatment: Single-dose administration by the epidural route, at the lumbar level, for the treatment of pain following major surgery

Dosage: INJECTABLE, LIPOSOMAL;EPIDURAL

Strength	Dosage	Availability
15MG/1.5ML (10MG/ML)	INJECTABLE, LIPOSOMAL;EPIDURAL	Discontinued
20MG/2ML (10MG/ML)	INJECTABLE, LIPOSOMAL;EPIDURAL	Discontinued
10MG/ML (10MG/ML)	INJECTABLE, LIPOSOMAL;EPIDURAL	Discontinued

DEPODUR family patents

4. Morphabond Er patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10314788	OHEMO LIFE	Pharmaceutical compositions configured to deter dosage form splitting	Aug, 2028 (4 years from now)
US7955619	OHEMO LIFE	Abuse resistant drugs, method of use and method of making	Aug, 2028 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-189)	Oct 02, 2018

Market Authorisation Date: 02 October, 2015

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
15 mg, 30 mg, 60 mg and 100 mg	28 Jan, 2019	1		21 Aug, 2028

Strength	Dosage	Availability
100MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
60MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
30MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
15MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

MORPHABOND ER family patents

5. Morphine Sulfate patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072781	FRESENIUS KABI USA	Morphine formulations	Mar, 2034 (9 years from now)
US9192608	FRESENIUS KABI USA	Morphine formulations	Mar, 2034 (9 years from now)
US9248229	FRESENIUS KABI USA	Packaging system for oxygen-sensitive drugs	Mar, 2034 (9 years from now)

Market Authorisation Date: 30 October, 2013

Treatment: Treatment of pain

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS